VA Portland Health Care System (VAPORHCS) joined a growing roster of institutions participate in the 3D-PREDICT clinical trial seeking to validate the sponsor’s test as a patient-specific predictor of response to cancer therapies for patients with the aggressive form of brain cancer called glioblastoma.
The prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient’s own biopsy or resected tumor tissue for assessing tissue response to therapy in patients with advanced cancers such as Ovarian and Glioblastoma multiforme. Targeting 570 participants, study sponsor KIYATEC launched the study in June 2018 and concludes the endeavor by June 2022. Several sites are involved including VAPORHCS.
VAPORHCS is a 227-bed acute care medical center in Portland, OR. Opened in 1929 and now adjacent to Oregon Health & Sciences University, the original hospital was replaced in the 1980s and has a capacity of up to 478 beds. Services include primary care, radiology, speech and language pathology, social work, prosthetics, rehabilitation, emergency care, a phar...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).